Thomas Quack / Shutterstock.com
9 August 2019AmericasSarah Morgan
Bayer buys BlueRock to build cell therapy expertise
Bayer is set to acquire the rest of BlueRock Therapeutics, in a deal that values the Massachusetts-based cell therapy company at $1 billion.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Americas
21 August 2019 Bayer has agreed to sell its animal health business to US-based Elanco Animal Health for $7.6 billion, as part of its strategic plan to focus on its core life sciences businesses.
Editor's picks
Editor's picks
Americas
21 August 2019 Bayer has agreed to sell its animal health business to US-based Elanco Animal Health for $7.6 billion, as part of its strategic plan to focus on its core life sciences businesses.
Americas
21 August 2019 Bayer has agreed to sell its animal health business to US-based Elanco Animal Health for $7.6 billion, as part of its strategic plan to focus on its core life sciences businesses.